Dovitinib enhances temozolomide efficacy in glioblastoma cells

Thatchawan Thanasupawat†, Suchitra Natarajan†, Amy Rommel2†, Aleksandra Glogowska1, Hugo Bergen1, Jerry Krcek1,3, Marshall Pitz4, Jason Beiko3, Sherry Krawitz5, Inder M. Verma2, Saeid Ghavami1, Thomas Klonisch1,3,6† and Sabine Hombach-Klonisch1,7†

1 Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada
2 Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA, USA
3 Department of Surgery, University of Manitoba, Winnipeg, Canada
4 Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
5 Department of Pathology, University of Manitoba, Winnipeg, Canada
6 Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
7 Obstetrics, Gynecology and Reproductive Medicine, College of Medicine, University of Manitoba, Winnipeg, Canada

Keywords
DNA damage; dovitinib; glioblastoma; HMGA2; temozolomide

Correspondence
S. Hombach-Klonisch, Department of Human Anatomy and Cell Science, College of Medicine, Faculty of Health Sciences, University of Manitoba, 130-745 Bannatyne Avenue, Winnipeg, MB R3E 0J9, Canada
Fax: +1 204 789 3920
Tel: +1 204 789 3982
E-mail: sabine.hombach-klonisch@umanitoba.ca

†These authors contributed equally

(Received 19 April 2017, accepted 25 April 2017, available online 5 June 2017)

doi:10.1002/1878-0261.12076

The multikinase inhibitor and FDA-approved drug dovitinib (Dov) crosses the blood–brain barrier and was recently used as single drug application in clinical trials for GB patients with recurrent disease. The Dov-mediated molecular mechanisms in GB cells are unknown. We used GB patient cells and cell lines to show that Dov downregulated the stem cell protein Lin28 and its target high-mobility group protein A2 (HMGA2). The Dov-induced reduction in pSTAT3Tyr705 phosphorylation demonstrated that Dov negatively affects the STAT3/LIN28/Let-7/HMGA2 regulatory axis in GB cells. Consistent with the known function of LIN28 and HMGA2 in GB self-renewal, Dov reduced GB tumor sphere formation. Dov treatment also caused the downregulation of key base excision repair factors and O6-methylguanine-DNA-methyltransferase (MGMT), which are known to have important roles in the repair of temozolomide (TMZ)-induced alkylating DNA damage. Combined Dov/TMZ treatment enhanced TMZ-induced DNA damage as quantified by nuclear γH2AX foci and comet assays, and increased GB cell apoptosis. Pretreatment of GB cells with Dov (‘Dov priming’) prior to TMZ treatment reduced GB cell viability independent of p53 status. Sequential treatment involving ‘Dov priming’ and alternating treatment cycles with TMZ and Dov substantially reduced long-term GB cell survival in MGMT+ patient GB cells. Our results may have immediate clinical implications to improve TMZ response in patients with LIN28+/HMGA2+ GB, independent of their MGMT methylation status.

Abbreviations
APE1, Apurinic/apyrimidinic endonuclease 1; BBB, Blood–brain barrier; BER, base excision repair; DNA, Deoxyribonucleic acid; Dov, Dovitinib; ES, Embryonic stem cells; FBS, Fetal bovine serum; FEN1, Flap structure-specific endonuclease 1; FGFR, Fibroblast growth factor receptor; GB, Glioblastoma; HMGA2, High-mobility group protein A2; IHC, Immunohistochemistry; KD, Knockdown; MGMT, O6-methylguanine-DNA methyltransferase; MMS, Methyl methanesulfonate; MPG, N-Methylpurine DNA glycosylase; PARP1, Poly(ADP-ribose) polymerase 1; PCR, polymerase chain reaction; PDGF, Platelet-derived growth factor; PI, Propidium iodide; PKC, Protein kinase C; RNA, Ribonucleic acid; SHP1, SH2 domain-containing protein tyrosine phosphatase; STAT3, Signal transducer and activator of transcription 3; TMZ, temozolomide; VEGF, Vascular endothelial cell growth factor; WB, western blot; XRCC1, X-ray repair cross-complementing protein 1; γH2AX, phosphorylated histone 2A (Ser 139).
1. Introduction

The FDA-approved oral drug dovitinib (Dov; TKI258, CHIR258; DOV) inhibits the tyrosine kinases FGFR, PDGFR-β, VEGFR, and c-KIT, has manageable toxicity, and distributes extensively in tissues (Dubbelman et al., 2012). In addition to its multityrosine kinase inhibitory functions, Dov binds to the DNA minor groove and acts as a topoisomerases I and II poison causing DNA damage (Hasinoff et al., 2012). Several phase I/II/III clinical trials revealed that when used as monotherapy, Dov showed only moderate overall efficacy in patient in a variety of solid tumors (Angevin et al., 2013; Kang et al., 2013; Keam et al., 2015; Kim et al., 2011; Lim et al., 2015; Motzer et al., 2014; Sarkar et al., 2008; Scheid et al., 2015). Increased sensitivity to Dov was reported in patients with a RETG207A germline variant (Quintela-Fandino et al., 2014) and in BRAF-mutant metastatic melanoma (Langdon et al., 2015), FGFR2-mutant endometrial cancer cells (Konecny et al., 2013), and BCR-ABL+ leukemia cells (Eucker et al., 2014). A beneficial role of Dov comes from combinatorial therapies. In vitro and mouse xenograft studies demonstrated a significant benefit in using a combined treatment of Dov with platinum compounds in colon cancer (Gaur et al., 2014) and with mTOR inhibitors in hepatocellular (Chan et al., 2013) and basal cell breast carcinoma (Issa et al., 2013). The combination of Dov and mTOR inhibitor was also found effective in two clinical trials with metastatic renal cancer patients (Blesius et al., 2013; Escudier et al., 2014), whereas a third trial study reported only modest activity in patients with VEGF-refractory clear cell renal cancer (Powles et al., 2014). A combination of Dov and the antiangiogenic drug fulvestrant (ICI-182.780) showed a significant in vitro antiproliferative activity in human endometrial cancer cells (Eritja et al., 2014) and promising clinical activity in a phase II trial with hormone receptor-positive, HER2+ breast cancer patients (Musolino et al., 2017).

Highly malignant glioblastoma (GB) constitutes 50–60% of primary brain tumors and has one of the worst five-year survival rates among all human cancers (Krex et al., 2007). The primary chemotherapeutic drug of choice is the DNA-alkylating agent temozolomide (TMZ). However, fast growth, the ability to bypass drug actions, and inferior local drug concentrations contribute to inevitable recurrences resulting in fatal chemoresistant forms of GB. Encouraged by the ability of DOV to cross the blood–brain barrier (BBB) (Schafer et al., 2016), two clinical trials were initiated in Germany [NCT01753713] and the United States [NCT01972750] to determine whether DOV monotherapy can benefit patients with advanced and recurrent glioblastoma (GB). Recently, first results from the German trial demonstrated efficacy in some recurrent GB patients and recommended additional personalized trials (Schafer et al., 2016).

The tumor-specific responses to Dov and the current lack of studies on molecular mechanisms of Dov action in GB pose a challenge to the development of effective personalized therapeutic strategies. In several human tumor models, Dov was shown to inhibit the MAPK, PI3K/AKT/mTOR, STAT3/5, and/or Wnt signaling pathways (Chase et al., 2007; Chon et al., 2016; Lopes de Menezes et al., 2005; Trudel et al., 2005; Zang et al., 2015). While the tyrosine kinase receptor inhibitory function of Dov frequently coincided with reduced activity of some of these signaling pathways (Lee et al., 2005, 2015; Lopes de Menezes et al., 2005; Piro et al., 2016; Valiente et al., 2014; Wang et al., 2016), tyrosine kinase receptor-independent mechanisms of Dov also occur. This includes Dov-mediated activation of protein tyrosine phosphatase SHP-1 and subsequent dephosphorylation of phospho-(p)STAT3TYR705, resulting in the downregulation of antiapoptotic STAT3 target genes McI1 and survivin, and G1/S cell cycle promoting cyclin D1 (Chen et al., 2012; Tai et al., 2012). The inhibition of pSTAT3TYR705 was shown to be dependent on SHP-1 in colorectal (Fan et al., 2015) and hepatocellular carcinoma (Huang et al., 2016).

High-mobility group protein A2 (HMGA2) is a nuclear nonhistone chromatin binding protein expressed in embryonic, fetal, and many cancer cells/tissues, but is usually undetectable in normal adult somatic cells (Gattas et al., 1999). Its three AT-hook DNA binding domains interact with the minor groove at AT-rich DNA sites and have intrinsic AP/dRP lyase activities that remove cytotoxic deoxyribosephosphate (dRP) sites to facilitate expedient base excision repair (BER) and protect HMGA2+ embryonic stem (ES) cells and cancer (stem) cells from genomic instability and apoptosis (Natarajan et al., 2013; Summer et al., 2009). HMGA2 affects mesenchymal differentiation and ES cell proliferation (Li et al., 2007) and tissue-specific overexpression of full-length HMGA2 causes mesenchymal tumors (Mayr et al., 2007; Zaidi et al., 2006). High cellular HMGA2 levels are linked to increased malignancy, enhanced metastatic potential, and poor clinical outcome in different cancer types (Fusco and Fedele, 2007; Rogalla et al., 1997). Ubiquitous expression of a truncated HMGA2 mRNA lacking the 3' untranslated region (UTR) which contains Let-7 microRNA binding sites can result in lipomas...
and cancer (Battista et al., 1999; Yu et al., 2007). HMGA2 is part of a larger STAT3/LIN28/Let-7/HMGA2 axis with important oncogenic functions in a subset of GB and breast cancer cells (Guo et al., 2013; Han et al., 2013; Mao et al., 2013). TCGA data analysis revealed increased gene expression of HMGA2 in the mesenchymal GB subtype compared to the glioma CpG island methylator phenotype (G-CIMP subtype) and up to 2% of GB patients harbor HMGA2 gene amplifications as determined by cBioPortal (Jiang et al., 2016). Like HMGA2, the stem cell factor and Let-7 binding protein LIN28A confers a poor prognosis in a subset of patients with GB. LIN28A-positive GBs express high levels of HMGA2 with associated high invasiveness (Mao et al., 2013). HMGA2 is an important prognostic marker in patients with GB, and HMGA2 expression in GB tissues correlates with significantly reduced progression-free survival time (Liu et al., 2014; Mao et al., 2013).

In the present study, we provide first evidence in human GB cell lines and patient GB cells that Dov attenuated the STAT3/LIN28/Let-7/HMGA2 axis and downregulates BER factors and MGMT, a known predictor of TMZ resistance in GB. Dual or sequential treatment with Dov and TMZ enhanced the efficacy of TMZ, reduced GB cell survival, and resulted in reduced tumor sphere formation with decreased cell viability of sphere-forming GB cells.

2. Materials and methods

2.1. Cell culture

Authenticated human glioma cell lines U251 and U87 were cultured in Dulbecco’s modified Eagle’s medium and F-12 1 : 1 (DME-F12; Hyclone, Thermo Fisher Scientific, Burlington, ON, Canada) plus 10% fetal bovine serum (FBS; Sigma, Oakville, ON, Canada). Patient GB cells were isolated from tissues obtained from GB patients treated at the Health Science Centre (Glogowska et al., 2013). The study was approved by the University of Manitoba and Pathology ethics boards, and written consent was obtained from the patients. Tumor sphere formation was performed and the mouse GB-initiating cell line NF53 was established as described (Friedmann-Morvinski et al., 2012; Thanasupawat et al., 2015).

2.2. Orthotopic transplantation and xenograft model

All procedures performed were approved by the IACUC. A total of $3 \times 10^5$ mouse GB-initiating NF53 cells suspended in 1–1.5 μL of HBSS were stereotactically injected into the right hippocampus of B6 mice (Friedmann-Morvinski et al., 2012). Forty-μm-thick coronal sections from perfusion-fixed NF53 xenografts were cut on a sliding microtome and imaged by a Zeiss LSM 710 laser scanning confocal microscope (Zeiss, Jena, Germany). Mouse tumor-bearing brain sections perfused with 4% PFA were washed in PBS, then blocked for 1 h with 3% donkey serum, 0.25% Triton X-100, and probed for HMGA2 (1 : 250). The intracranial U87lin xenograft experiments were approved by the University of Manitoba animal ethics board and carried out as described (Thanasupawat et al., 2015). Brains were fixed in buffered formalin and processed for histology and immunohistochemistry (IHC).

2.3. Quantitative Real-time PCR

Using 1 μg of total RNA and random primer (Promega, Madison, WI, USA), cDNA was synthesized at 65 °C for 5 min, 25 °C for 10 min, 42 °C for 50 min, and 70 °C for 15 min. Quantitative real-time PCR (qPCR) was carried out with QuantiStudio® 3 (Applied Biosystems, Thermo Fisher Scientific) using PowerUp TM SYBR® green Master mix (Applied Biosystems). The following primers were used for amplification: F-HMGA2 5'-GGGCCCTCAGAGGAGGAC3'; R-HMGA2 5'-TTGAGCTGCTTTAGAGGGACTC-3'; F-GAPDH 5'-GTCTCCTCTGACTTCAACACTCAAGCG-3'; R-GAPDH 5'-ACCACCCCTGTTGCTGTAGCCAA-3'. The relative HMGA2 expression was analyzed by comparative cycle threshold (Ct) method and normalized to GAPDH.

2.4. Western blot

Protein lysates were separated by SDS/PAGE and blotted onto a nitrocellulose membrane. Membranes were blocked for 1 h at room temperature (RT) with 5% milk in Tris-buffered saline containing 0.1% Tween-20 (TBST), pH 7.6, prior to probing with antibodies. Primary antibodies to HMGA2 (1 : 1000), HMGA1 (1 : 1000), γH2AX (1 : 1000), phospho-STAT3 (pSTAT3 Tyr705; 1 : 1000), total STAT3 (2 : 1000), PARP1 (1 : 2000), XRCC1 (1 : 1000), PKCa (1 : 1000), p21 (1 : 1000), α-tubulin, MGMT (1 : 1000; all rabbit polyclonal IgG, Cell Signaling, via New England Biolabs, Whitby, ON, Canada), lamin a/c (1 : 500 (goat polyclonal antibody) and p53 (1 : 2000; both from SantaCruz, CA, USA), FEN-1 (1 : 1000, Bethyl Laboratories, Montgomery, TX, USA), MPG (1 : 3000), Ape-1 (1 : 2000, both Abcam,
Dovitinib increases TMZ efficacy in GB

T. Thanasupawat et al.

Toronto, Canada), cathepsin B (1 : 100; gift from E. Weber, Germany), LIN28A (1 : 1000; rabbit polyclonal antibody; Cedarlane, Burlington, ON, Canada), and β-actin (1 : 10,000; Sigma) were probed overnight at 4 °C followed by incubation for 1 h at RT with HRP-conjugated anti-rabbit (Cell Signaling), anti-goat, and anti-mouse (Sigma) secondary antibodies.

2.5. DNA damage detection

For immunofluorescence detection of nuclear phosphorylated γH2AX, GB cells were fixed in 3.7% formaldehyde, permeabilized with 0.2% Triton X-100, and nonspecific sites were blocked with 4x SSC/4% BSA for 1 h at RT. Primary antibodies to phosphorylated γH2AX (1 : 5000; mouse monoclonal; EMD Millipore, Missisauga, ON, Canada) were incubated with blocking buffer for 2 h at RT followed by incubation with Alexa Fluor-594-conjugated goat anti-mouse IgG (Life Technologies, via Thermo Fisher Scientific) for 1 h at RT. Cells were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI; Sigma) and mounted with Fluoromount aqueous mounting medium. Images were acquired using a Zeiss upright fluorescence Z2 microscope (Plan-APOCHROMAT 63x/1.4 Oil DIC objective) with monochrome CCD camera (Zeiss). For the alkaline comet assays, 50,000 U251 and U251-HMGA2 cells were plated in six-well plates for comet assay. Cells were incubated with different concentrations of TMZ (0.5 mM, 1 mM, 1.5 mM) for 24 h, followed by 72-h treatments with 100 μm TMZ, which represents a dose equivalent to concentrations achieved in patient GB (Portnow et al., 2009) and is commonly used in cell culture experiments (Kitange et al., 2009). For short-term readouts of toxicity, we used 24-h treatments with IC50 TMZ in human and mouse GB cells. Human GB cells were also treated with Dov (Sigma) at 1–5 μm as indicated. WST-1 reagent (Roche Diagnostics, Laval, QC, Canada) was added and absorbance was measured at 450 nm after 4 h using a plate reader (Molecular Devices, Sunnyvale, CA, USA). For cytotoxicity in sphere-forming cells, U87 cells were grown as tumor spheres in stem cell medium for 7 days. Spheres were dissociated as single cells and 5000 sphere-forming cells/well in stem cell medium were seeded in a 96-well plate for WST cytotoxicity and caspase 3/7 apoptosis assays following treatments with Dov and siHMGA2 as indicated.

The xCelligence system (ACEA Biosciences, Inc., San Diego, CA, USA) was used to determine real-time cellular response of primary GB cells upon treatment with TMZ (100 μm) and Dov (1, 2, 5 μm) over 96 h. The system measured the cellular impedance across microelectrodes integrated on the bottom of 16-well E-plates. Cell viability, cell number, cell morphology, and degree of adhesion affect electrode impedance. Cells (5000 cells per well) were seeded in 96 well E-plates containing DME/F12 media with 10% FBS. Cells were exposed to 100 μm TMZ and different concentrations of Dov (1, 2, 5 μm). Impedance measurements for real-time monitoring occurred every 1 min.

2.6. Immunohistochemistry

Forty-μm-thick coronal sections from perfusion-fixed NF53 xenografts were cut using a Vibratome and processed for standard immunohistochemical staining. Mouse tumor-bearing brain sections perfused with 4% PFA were washed in PBS, then blocked for 1 h with 3% donkey serum, 0.25% Triton X-100, and probed for HMGA2 (1 : 250). Images were acquired with a Zeiss LSM 710 laser scanning confocal microscope (Zeiss). IHC for HMGA2 in U87 xenograft sections and human GB tissues (5 μm) was performed as described (Thanasupawat et al., 2015). Tissue sections were counterstained with hematoxylin prior to imaging with a Zeiss A2 microscope (Zeiss).

2.7. Cytotoxicity assay

For cytotoxicity assays, human GB cells and mouse NF53 cells (5000 cells per well) were seeded in a 96-well plate, cultured overnight, and treated with HMGA2 siRNA (#SASI-HS01 000 98053, Sigma) for 24 h, followed by 72-h treatments with 100 μm TMZ, which represents a dose equivalent to concentrations achieved in patient GB (Portnow et al., 2009) and is commonly used in cell culture experiments (Kitange et al., 2009). For short-term readouts of toxicity, we used 24-h treatments with IC50 TMZ in human and mouse GB cells. Human GB cells were also treated with Dov (Sigma) at 1–5 μm as indicated. WST-1 reagent (Roche Diagnostics, Laval, QC, Canada) was added and absorbance was measured at 450 nm after 4 h using a plate reader (Molecular Devices, Sunnyvale, CA, USA). For cytotoxicity in sphere-forming cells, U87 cells were grown as tumor spheres in stem cell medium for 7 days. Spheres were dissociated as single cells and 5000 sphere-forming cells/well in stem cell medium were seeded in a 96-well plate for WST cytotoxicity and caspase 3/7 apoptosis assays following treatments with Dov and siHMGA2 as indicated.

The xCelligence system (ACEA Biosciences, Inc., San Diego, CA, USA) was used to determine real-time cellular response of primary GB cells upon treatment with TMZ (100 μm) and Dov (1, 2, 5 μm) over 96 h. The system measured the cellular impedance across microelectrodes integrated on the bottom of 16-well E-plates. Cell viability, cell number, cell morphology, and degree of adhesion affect electrode impedance. Cells (5000 cells per well) were seeded in 96 well E-plates containing DME/F12 media with 10% FBS. Cells were exposed to 100 μm TMZ and different concentrations of Dov (1, 2, 5 μm). Impedance measurements for real-time monitoring occurred every 1 min.

2.8. Apoptosis detection

For the quantification of caspase 3/7 activity, cells (5000 cells per well) were seeded in white-bottomed 96-well plates and cultured overnight. Following siRNA and drug treatments for the indicated time points, caspase activation was determined with the Caspase-Glo-3/7 reagent (Promega) and luminescence was determined with a plate reader after 1-h incubation at RT. We used a modified Nicoletti method to measure apoptosis by flow cytometry (Ghavami et al., 2009,
Dovitinib increases TMZ efficacy in GB

2.9. RNA silencing

The siRNA-mediated silencing was performed using siLentFect lipid reagent (Bio-Rad, Mississauga, ON, Canada) according to the manufacturer’s instructions. After 72 h of HMGA2 siRNA (Sigma and Dharmacon via Thermo Fisher Scientific), MGMT siRNA (Santa Cruz), and scrambled siRNA (Cell Signaling Technologies) treatments, WST assays and western blots were performed.

2.10. Sphere formation assay

Glioblastoma tumor spheres were grown for 7 days in low attachment plates and then dissociated, and individual sphere-forming cells (1,000/well) were seeded in low attachment 24-well plates for treatments. Dov or HMGA2 siRNA treatments were performed for 3 days, and sphere formation was determined after a total of 6 days. Numbers of spheres with a diameter > 50 μm per well were counted (Hong et al., 2012) using a 20× objective with a phase-contrast inverted microscope (Zeiss).

2.11. Colony formation assay

Two thousand cells per well were seeded in a six-well plate in triplicate and five cycles of alternating treatments of 5 μM Dov and 100 μM TMZ were performed every 3 days followed by recovery in normal growth medium for 9 days. At the end of the recovery period, the number of colonies formed was counted with a 20× objective under phase contrast with an inverted microscope (Zeiss).

2.12. Statistical analysis

Two-tailed unpaired t-tests and analysis of variance (ANOVA) were performed to determine the statistical significance among the different treatment groups. Post hoc tests were performed for multiple comparisons to ensure statistical significance. A P-value of less than 0.05 was considered statistically significant. Error bars represent the standard error of the mean (SEM).

3. Results

3.1. Dovitinib downregulates Lin28 and HMGA2

Although Dov has been used in clinical trials for the treatment of recurrent GB, the molecular mechanisms triggered by Dov in GB are largely unknown. We used patient GB cells and GB cell lines to show that Dov treatment downregulated both LIN28A (Fig. 1A) and HMGA2 (Fig. 1C). It was previously shown that Lin28 located upstream of HMGA2 can upregulate HMGA2 (Mao et al., 2013) and that HMGA2 promotes GB stem cell renewal and tumor initiation in GB cells (Zhong et al., 2016). In concordance with the Dov-mediated reduction in cellular Lin28 and HMGA2 levels, we showed that Dov reduced the number of GB spheres in a concentration-dependent manner (Fig. 1B). Similarly, we observed a reduced number of GB spheres upon siRNA-mediated silencing of HMGA2 in GB cells (Fig. S1).

We aimed to confirm the expression of HMGA2 in patient GB cells and in human and mouse GB tissues. Brain tumor allograft sections derived from mouse GFP+ green fluorescent NF53 brain tumor-initiating cells showed expression of HMGA2 (Fig. S2A) and stem cell marker nestin (Fig. S2B) in GFP+ NF53 brain tumor cells. IHC analysis of mouse allografts (Fig. S2C), xenografts derived from human U87MG glioma cells (Fig. S2D), and human GB tissues (Fig. S2E) all showed nuclear HMGA2 expression exclusively in GB cells. Patient GB cells isolated from GB tumors and the human glioma cell lines U251 and U87MG expressed HMGA2 transcripts (Fig. S2F), and we confirmed the nuclear localization of HMGA2 protein in GB cells by western blot analysis (Fig. S2G).
Western blot analysis confirmed that Dov treatment at concentrations as low as 2 μM downregulated HMGA2 protein in GB cells (Fig. 1C). In addition to the reduced Lin28A levels, we also observed a dramatic reduction in STAT3 phosphorylation at Tyr705 under low Dov concentrations. STAT3Tyr705 is a known upstream regulator for the Lin28/Let7/HMGA2 oncogenic pathway (Guo et al., 2013). We have identified Dov as a negative regulator of this pathway in GB cells. The Dov-mediated reduction in the STAT3/LIN28/Let-7/HMGA2 oncogenic pathway (Guo et al., 2013). We have identified Dov as a negative regulator of this pathway in GB cells. The Dov-mediated reduction in the STAT3/LIN28/Let-7/HMGA2 axis coincided with an increase in cellular levels of phosphorylated γH2AX, a known marker for double-strand (ds)DNA damage (Fig. 1C).

3.2. Dovitinib reduces BER factors and MGMT in GB cells

HMGA2 has a new member of the base excision repair (BER) family of proteins (Summer et al., 2009). Thus, we investigated whether Dov treatment affected other BER factors in GB cells. Low-dose Dov (1, 2, 5 μM) treatments over 72 h downregulated HMGA2 protein and decreased the BER members 3'-methyladenine DNA glycosylase (MPG), apurinic/apyrimidinic (AP) endonuclease 1 (APE-1), flap structure-specific endonuclease 1 (XRCC1), and poly (ADP-ribose) polymerase 1 (PARP1) (Fig. 2A). The Dov-mediated reduction in HMGA2 and BER protein levels in GB cells is consistent and selective for LIN28A, HMGA2, and these BER factors but did not extend to other proteins previously shown to be expressed and regulated in GB cells, including PKC alpha and cathepsin B (Glogowska et al., 2013) (Fig. S3A). Also, we observed only a marginal reduction in protein levels for the structural relative HMGA1 (Fig. S3A). As expected, Dov treatment failed to alter HMGA2 protein levels in stable U251-HMGA2 transfectants with constitutive exogenous overexpression of HMGA2 (Fig. S3B).
Dovitinib increases TMZ efficacy in GB

T. Thanasupawat et al.

Dov exposure (5 μM) elevated levels of γH2AX, indicating increased dsDNA damage in the absence of the alkylating drug TMZ (Fig. 2B,C). TMZ also increased γH2AX levels in U251 cells (Fig. 2B), but failed to do so in patient GB cells (Fig. 2C). Patient-derived GB-1 and GB-10 cells expressed MGMT protein, whereas U251 and U87MG cell lines lacked MGMT (Fig. 2D).

The clinical use of DNA-alkylating TMZ in GB prompted us to investigate whether Dov, in addition to its role in downregulating BER factors, can also affect cellular O6-methylguanine-DNA methyltransferase (MGMT) levels. MGMT repairs TMZ-induced O6-methylguanine base modification and promotes TMZ resistance in GB (Fukushima et al., 2009; Hegi et al., 2008; Stupp et al., 2009). Intriguingly, Dov (1, 2, 5 μM) treatment downregulated MGMT protein in patient GB cells (Fig. 2E). This MGMT downregulation by Dov occurred in the absence of TMZ, which is known to deplete cellular MGMT protein levels in GB (Hegi et al., 2008) (Fig. S4A). Treatment with TMZ (100 μM) failed to alter cellular LIN28A, HMGA2, MPG, and APE-1 levels and did not prevent the Dov-mediated reduction in these protein levels in GB (Figs 2B,C and S4B).

We addressed whether the Dov-mediated concurrent downregulation of HMGA2 and MGMT proteins could affect TMZ efficacy in GB cells by applying separate and combined siRNA-mediated KD of HMGA2 and MGMT. We determined the success of this KD treatment by western blot (Fig. 2F). Neither single nor double siRNA-mediated KD reduced viability in patient GB cells (Fig. S5). Following 24-h exposure to TMZ, we found that single HMGA2 KD induced similar levels of caspase 3/7 activation when compared to combined KD of both HMGA2 and MGMT (Fig. 2G), demonstrating that the loss of HMGA2, not a lack of MGMT, was responsible for promoting apoptosis under TMZ. The increase in TMZ-induced DNA damage under HMGA2 KD coincided with increased apoptosis as determined by caspase 3/7 activation (Fig. 2H). Silencing of endogenous HMGA2 increased and overexpression of exogenous HMGA2 decreased this apoptotic response under TMZ (Fig. 2H). Similar to human GB, NF53 mouse GB cells became sensitized to TMZ upon HMGA2 silencing and responding with increased caspase 3/7 activation and decreased cell viability (Fig. 2I,J), confirming a role for HMGA2 in antagonizing TMZ sensitivity. Our findings demonstrated a novel role of Dov in regulating TMZ sensitivity by attenuating expression of pSTAT3/LIN28/HMGA2, BER, and MGMT in GB cells.

3.3. HMGA2 expression is protective against DNA damage in GB cells

Our data demonstrated that HMGA2 protects GB cells against apoptosis induction by TMZ (Fig. 2G, H). To assess whether the DNA repair function of HMGA2 contributed to this protective effect, we investigated the TMZ-induced DNA damage in GB cells with high and low HMGA2 levels. We used U251 cells to silence endogenous HMGA2 using specific HMGA2 siRNA and confirmed by western blots the specific and efficient KD of HMGA2 within 48 h of siHMGA2 treatment (Fig. 3A). We also created U251 transfectants with stable expression of Flag-tagged HMGA2 (Fig. 2A). To assess whether HMGA2 silencing increased TMZ-induced DNA damage, we quantified γH2AX foci in U251 (Sharma et al., 2012). Upon 24 h of TMZ treatment (1.5 μM), increased numbers of bright γH2AX foci were detected in U251 (Fig. 3B). Quantification of these focal points showed increased γH2AX foci in U251 cells upon knockdown of HMGA2 (Fig. 3C).

Fig. 2. Dovitinib downregulates proteins involved in TMZ-induced DNA damage repair. (A) Low Dov concentrations at 1, 2, and 5 μM for 24 h, 48 h, and 72 h reduced the BER proteins APE1, MPG, FEN1, PARP1, and XRCC1 with most pronounced effects seen at 72 h as shown here for U251 and GB-10. (B) In U251, Dov at 5 μM downregulated LIN28 and HMGA2 and increased γH2AX levels at 72 h. TMZ (100 μM) alone did not downregulate Lin28 and HMGA2, but did not prevent Dov (5 μM)-induced reduction in these proteins in U251 cells. (C) Like with U251 cells, Dov at 5 μM downregulated HMGA2 and increased γH2AX levels at 72 h. TMZ (100 μM) at 72-h exposure did not decrease HMGA2 protein levels in GB-10 cells and did not prevent DOV (5 μM)-induced HMGA2 downregulation. (D) In contrast to the GB cell lines U87 and U251 which were negative for HMGA expression, patient GB cells expressed MGMT protein. (E) Dov consistently downregulated MGMT, shown here for GB-10. (F) Western blot showing specific KD of HMGA2 or MGMT and dual silencing in GB-10 cells. (G) Caspase 3/7 assays were performed. Individual silencing of HMGA2 and MGMT and dual HMGA2/MGMT KD showed that apoptosis was strongly induced at 24 h by TMZ (1.5 μM) in patient GB cells with silenced HMGA2, but not upon MGMT silencing or TMZ alone. (H) Compared to U251 cells with endogenous HMGA2, siHMGA2 KD significantly increased caspase 3/7 activity following treatment with TMZ. In contrast, high exogenous cellular HMGA2 levels reduced this caspase 3/7 activity upon TMZ. Similar to human GB cells, HMGA2 KD in mouse NF53 GB cells caused (l) an increase in caspase 3/7 activation, which was dramatically upregulated with TMZ, and (J) a reduction in cell viability over 24 h, which was aggravated by TMZ at EC50 (2 μM) for 24h. Graphs show SEM from three independent experiments; ***P < 0.001; **P < 0.01.
nuclear γH2AX foci revealed that HMGA2 KD alone caused a significant increase in the number of γH2AX foci in U251 when compared to nonsilencing control siRNA-treated cells (Fig. 3C). We observed a further dramatic increase in γH2AX foci in HMGA2-silenced GB cells upon TMZ treatment, indicating significant
dsDNA damage in HMGA2-depleted glioma cells (Fig. 3C). Similarly, NF53 mouse GB cells showed increased nuclear γH2AX foci upon HMGA2 KD and a further increase upon exposure to TMZ (Fig. 3D). The DNA strand breaks under TMZ exposure in U251 cells were confirmed by alkaline comet assays. We detected an increase in the olive tail moment when GB cells were exposed to increasing concentrations of TMZ (Fig. 3E). While the olive tail moment obtained with U251-HMGA2 transfectants also increased with higher TMZ concentrations, HMGA2 overexpression significantly mitigated dsDNA strand breaks compared to U251 cells (Fig. 3E). These results revealed a new role for HMGA2 in antagonizing TMZ-induced DNA damage in both human and mouse GB. Importantly, these results suggested that the Dov-mediated downregulation of HMGA2 may be a promising molecular mechanism to increase GB cell sensitivity to TMZ.

3.4. Dovitinib sensitizes GB cells to TMZ-induced apoptosis

The reduction in BER proteins and MGMT observed with Dov treatment encouraged us to investigate whether Dov treatment would increase GB cell sensitivity toward TMZ. Comet assays revealed that Dov (2 μM) and TMZ (100 μM) single treatment induced dsDNA strand breaks and dual Dov/TMZ treatment further increased this dsDNA damage upon treatment of U251 (Fig. 4A). In GB-10 patient cells, TMZ (100 μM) treatment failed to induce caspase 3/7 activation, whereas the addition of Dov (5 μM) triggered caspase 3/7 activation at 48 h (Fig. 4B). In U251 cells,
both TMZ (100 μM) and Dov (5 μM) single treatments induced caspase 3/7 activation after 48 h, but combined Dov/TMZ treatment failed to show an additive effect on caspase 3/7 activation (Fig. 4C). As caspase-independent mechanisms may contribute to apoptosis in patient GB cells, we used flow cytometry detection to quantify the PI-positive sub-G1 population of apoptotic cells following 48 h of treatment. Upon dual treatment with TMZ (100 μM) and Dov (2 μM) of GB-10, the apoptotic cell fraction in FACS analysis (20.48%) was similar to Dov monotherapy (2 μM; 18.43%), but had doubled when compared to single
treatment with TMZ (100 μM; 10.26%) (Fig. 5A). When the Dov concentration was increased to 5 μM, apoptosis increased further under combined Dov/TMZ (50.6%) and Dov alone (40.2%). In U251 cells, the apoptotic cell fraction was higher than in GB 10 cells with single TMZ (100 μM; 13.92%) or DOV (2 μM; 21.81%) exposure and reached 28.27% with the combined treatment (Fig. 5B), demonstrating a strong proapoptotic effect of Dov and the combined Dov/TMZ treatment. High cellular levels of HMGA2, as tested for the U251-HMGA2-overexpressing clone, reduced the apoptotic cell fraction of the combined Dov/TMZ treatment (23.59%) compared to U251 parental cells (28.27%) at 2 μM Dov (Fig. 5C). This anti-apoptotic effect of HMGA2 was more pronounced in U251-HMGA2 exposed to 5 μM Dov alone (27.04%) and Dov/TMZ combined treatment (26.73%) as compared to U251 parental cells with 38.48% and 44.91%, respectively. These results suggested that a combined Dov/TMZ treatment may be advantageous in reducing GB cell survival.

3.5. Combined treatment with dovitinib and TMZ reduces GB cell survival

Real-time cell survival assays (RTCA) performed with patient GB cells showed that TMZ (100 μM) reduced the cell index, a measure of cell viability, over time but still allowed a steady cell proliferation over 96 h to reduce cell viability by only 23% (Fig. 6). Single Dov exposure at low concentrations (1 μM) and the combined Dov/TMZ treatment significantly reduced the cell index, resulting in a 70% reduction in cell viability over the monitored 96-h time period (Fig. 6). We reasoned that downregulation of HMGA2, MGMT, and BER members under low-dose Dov treatment may sensitize GB cells toward TMZ. To test this, we devised a sequential treatment starting with ‘Dov priming’ to attenuate cellular HMGA2, BER, and MGMT capacities, followed by TMZ exposure of the GB cells (Fig. 7A). Upon 72 h of pretreatment with Dov (5 μM) and subsequent 72-h exposure to TMZ (100 μM), we observed a 40% reduction in cell viability in patient GB cells (Fig. 7B), which increased further to 50% upon subsequent additional Dov treatment (Fig. 7B). Similar results were found in U251 cells (Fig. 7C). Low-dose TMZ treatment alone or the reversed sequence of exposure resulted in <10% loss of viability in GB cells (Fig. 7B, C).

Next, we investigated whether a sequential treatment regimen can affect long-term survival of GB cells. To assess whether the observed loss in GB viability coincided with reduced GB cell survival after recovery from treatments, we performed colony formation assays with U251 cells and patient GB cells. We exposed GB cells to alternating low-dose Dov followed by low-dose TMZ treatments for 3 days each over a 15-day time period and determined colony formation after a 9-day recovery phase in growth medium without drugs added (Fig. 8A-I). Colony formation was compared to treatment with low-dose TMZ alone but lacking the Dov priming and intermittent Dov exposure steps prior to the recovery phase (Fig. 8A-II). Compared to TMZ treatment alone, Dov priming with subsequent alternation of TMZ and Dov exposure drastically reduced colony formation in U251 and almost inhibited survival of patient GB-10 cells (Fig. 8B,C). We confirmed that MGMT and HMGA2 downregulation in GB-10 and HMGA2 downregulation in U251 persisted throughout the entire sequential alternating Dov/TMZ treatment regimen (Fig. S6). Based on these results, we concluded that this novel sequential dual-hit Dov/TMZ treatment increases TMZ efficacy, reduces HMGA2-mediated antiapoptotic activity, and dramatically reduces the long-term survival in GB cells following TMZ treatment. Importantly, Dov priming was effective in MGMT+ GB cells and independent of P53 mutation status (Fig. S7).

Furthermore, our novel finding that HMGA2 also mitigated DNA damage induced by radiation (Fig. S8) may suggest that Dov-mediated downregulation of HMGA2 in GB cells may serve as a molecular mechanism to radiosensitize GB.

4. Discussion

The current standard treatment for GB includes surgical debulking followed by treatment with the DNA-alkylating agent TMZ and radiation therapy. However, this therapy frequently fails to prevent the development of resistance and fatal recurrences. There is an urgent need to identify drugs which help to sensitize GB cells to chemotherapeutic and radiation therapy. Based on its multikinase inhibitory function and the ability to cross the BBB (Schafer et al., 2016), the FDA-approved drug dovitinib (TKI258, CHIR258) has been tested as monotherapy in clinical trials for patients with advanced and recurrent GB in Germany [NCT01972750] and the United States [NCT01753713]. First results from the German trial demonstrated efficacy in some recurrent GB patients and recommended additional personalized trials (Schafer et al., 2016). Currently, no information is available on the molecular mechanisms by which Dov affects GB cells.

Our data in GB cells showed that Dov downregulates the stem cell factor and RNA-binding protein
Lin28A and its target HMGA2, identifying a hitherto unknown role of Dov as an inhibitor of the LIN28/Let-7/HMGA2 axis in human GB. In agreement with the well-known function of HMGA2 in promoting self-renewal of stem cells (Zhong et al., 2016) and GB tumor initiation capability (Kaur et al., 2016), Dov...
Dovitinib increases TMZ efficacy in GB

T. Thanasupawat et al.

A

GB-10

Control

10.26
Sub-G₁

TMZ-100 μM

18.43
Sub-G₁

TMZ + Dov 2 μM

20.48
Sub-G₁

Dov-5 μM

40.2
Sub-G₁

TMZ + Dov-5 μM

50.6
Sub-G₁

B

U251 parental

Control

4.54
Sub-G₁

TMZ-100 μM

13.92
Sub-G₁

TMZ + Dov 2 μM

28.27
Sub-G₁

Dov-5 μM

38.48
Sub-G₁

TMZ + Dov-5 μM

44.91
Sub-G₁

C

U251/HMGA2

Control

4.44
Sub-G₁

TMZ-100 μM

17.64
Sub-G₁

TMZ + Dov 2 μM

23.59
Sub-G₁

Dov-5 μM

27.04
Sub-G₁

TMZ + Dov-5 μM

26.73
Sub-G₁
**Fig. 5.** Combined TMZ and dovitinib treatment increases cell death. GB cells were treated with 100 μM TMZ alone, 2 μM and 5 μM Dov alone or in combination with 100 μM TMZ and the percentage of apoptotic cells (sub-G1 population) was quantified by PI flow cytometry after 48 h in GB-10 (A), U251 (B), and U251/HMGA2-overexpressing (C) cells. The % apoptotic cell fraction gated in M2 (sub-G1 subpopulation) is indicated for each cell line and treatment. HMGA2 overexpression mitigated the apoptotic response to Dov alone and to the combined Dov/TMZ treatment, and this effect was pronounced at 5 μM Dov (C). Representative FACS results of three independent experiments are shown.

**Fig. 6.** Dovitinib enhances TMZ-induced cytotoxicity. The xCelligence impedance-based real-time cell monitoring over 96 h under low-dose Dov (1 μM) and TMZ (100 μM) demonstrated that Dov plus TMZ combined had increased cytotoxic effects on GB-10 cells and resulted in stunted cell proliferation when compared to either drug alone. TMZ (100 μM) alone only moderately blocked GB cell growth. The column graphs show the cell index (Y-axis) during 24 h, 48 h, and 72 h of exposure averaged from three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05.

**Fig. 7.** Sequential dovitinib/TMZ treatment increases toxicity. We performed sequential treatment with Dov and TMZ. (A) Schematic representation of the sequential treatment strategy over 7 days using Dov (5 μM) and TMZ (100 μM) in GB-10 and U251. WST assays were performed to determine the percentage cell viability of (B) GB-10 and (C) U251 after pretreatment with 5 μM Dov for 3 days, followed by 3 days with 100 μM TMZ and 1 day of 5 μM Dov. No treatment controls (NT) and single TMZ or Dov treatment controls were employed. Graphs show SEM from three independent experiments; ***P < 0.001; **P < 0.01; *P < 0.05.
Fig. 8. Alternating dovitinib/TMZ treatments reduce cell survival upon recovery. (A) Schematic representation of the alternating Dov (5 μM) and TMZ (100 μM) treatment plan, 3 days each and 1 day of 5 μM Dov, for U251 and GB-10 followed by a nine-day cell recovery phase in normal medium without drugs. Survival of GB cells was determined by their ability to form colonies as quantified at the end of the recovery time. (B) Representative phase-contrast images are shown. (C) Alternating treatments with Dov and TMZ every 3 days for a total of 15 days followed by a recovery phase for 9 days (I) significantly reduced the number of colonies by >75% when compared to alternating treatment with TMZ alone (II), as shown for U251. Graphs show SEM from three independent experiments; ***P < 0.001.
attenuated GB sphere formation and increased apoptosis in sphere-forming GB cells. HMGA2 expression is controlled by specific Let-7 microRNA members that bind to the 3′UTR of HMGA2 to cause reduced mRNA stability and translation (Hammond and Sharpless, 2008). LIN28 upregulates HMGA2 by inactivating Let-7 family members (Droge and Davey, 2008; Hammond and Sharpless, 2008; Weingart et al., 2015) and LIN28 is expressed in GB patients with poor prognosis (Qin et al., 2014). Furthermore, HMGA2 is present in a LIN28A expressing subset of GB (Mao et al., 2013). We confirmed the expression of HMGA2 in nestin+ GB progenitors in our mouse allografts and showed nuclear HMGA2 expression in human orthotopic GB xenografts and human GB tissues. Dov also reduces the cellular levels of phospho-(p)STAT3 Tyr705 in GB cells. Thus, by altering the phosphorylation status of STAT3, Dov targets the STAT3/LIN28/Let-7/HMGA2 axis, which is emerging as an important oncogenic pathway for HMGA2 regulation in a subset of GB and breast cancer cells (Guo et al., 2013; Han et al., 2016; Mao et al., 2013). Dov was shown to activate the protein tyrosine phosphatase SHP-1, which resulted in the consecutive dephosphorylation of pSTAT3 Tyr705 and downregulation of the antiapoptotic STAT3 target genes Mcl1 and survivin, in a subset of GB and breast cancer cells (Guo et al., 2013; Han et al., 2016; Mao et al., 2013). Dov was shown to activate the protein tyrosine phosphatase SHP-1, which resulted in the consecutive dephosphorylation of pSTAT3 Tyr705 and downregulation of the antiapoptotic STAT3 target genes Mcl1 and survivin, and G1/S cell cycle factor cyclin D1 (Chen et al., 2012; Tai et al., 2012). STAT3 activation is known to promote self-renewal and tumorigenicity in stem-like GB cells (Gong et al., 2015) and is associated with radiosensitivity in GB (Maachani et al., 2016). The inactivation of pSTAT3 Tyr705 was shown to depend on SHP-1 in colorectal (Fan et al., 2015) and hepatocellular carcinoma (Huang et al., 2016). Dov-mediated downregulation of LIN28A and HMGA2 may, thus, be the result of enhanced SHP-1 in GB cells. STAT3 activation is promoted by cytokines such as IL-6 (Zhong et al., 1994), and the poor survival of GB patients with upregulated IL-6 and HMGA2 (Chiou et al., 2013) demonstrates the urgent need for therapeutic targeting of regulatory pathways upstream of HMGA2 in patients with GB.

We showed that Dov caused increased DNA damage in GB cells as detected by γH2AX foci and comet assays. The observed inhibitory effects of Dov on BER factor, HMGA2, and MGMT protein expression indicate that the origin of the Dov-mediated dsDNA breaks is likely complex and may involve different mechanisms. Apart from its multikinase inhibitory activity, Dov is an inhibitor of the catalytic relaxation activity of topoisomerase I and blocks the decatenation activity of topoisomerase II (Hasinoff et al., 2012). The resulting single- and double-strand DNA breaks cause stalled DNA replication/transcription and trigger apoptosis (Nitiss, 2009). The Dov-induced decrease in BER factors (MPG, APE-1, FEN1, PARP1, XRCC1) is anticipated to attenuate single-strand BER functions and enhance the occurrence of lethal dsDNA breaks (Davidson et al., 2013; Woodhouse et al., 2008). Another way of Dov to initiate DNA damage may involve HMGA2, which has recently been shown to augment topoisomerase I activity in a ternary complex with DNA and antagonize the topoisomerase I poison irinotecan/SN-38 (Peter et al., 2016). Attenuated HMGA2 expression may negatively affect topoisomerase I functions in GB. It remains to be seen whether Dov can alter topoisomerase I expression in GB. Reduced HMGA2 levels under Dov are also expected to compromise the ability of HMGA2 to support BER (Summer et al., 2009).

Reduced BER capacity under Dov is expected to impair the repair of the three TMZ-induced alkylated DNA base modifications N7-methylguanine (N7-MeG; 60–80%), N3-methyladenine (N3-MeA; 10–20%), and O6-methylguanine (O6-MeG; 5–10%) (Bobola et al., 2012). While the former two lesions are repaired by BER (Tang et al., 2011), O6-methylguanine-DNA methyltransferase (MGMT) specifically repairs O6-MeG sites and is known to promote TMZ resistance in GB (Fukushima et al., 2009; Hegi et al., 2008; Stupp et al., 2009). Dov causes sustained downregulation of MGMT, suggesting that Dov can compromise this TMZ resistance mechanism in GB. These findings led us to hypothesize that Dov may sensitize GB toward TMZ-induced cell death. MGMT−/− U251 cells were more sensitive to single TMZ or Dov treatment than MGMT+ patient GB cells as shown by caspase 3/7 activation assays. Upon TMZ treatment, MGMT−/− U251 glioma cells undergo mismatch repair (MMR) cycles with resulting dsDNA breaks and caspase 3/7-dependent apoptosis in subsequent cell cycles (Quiros et al., 2010). Both MGMT−/− U251 and MGMT+ patient GB cells showed a significant increase in caspase activation and PI-positive apoptotic cell fraction when exposed to dual low-dose Dov/TMZ treatment. Targeted single and dual siRNA KD of HMGA2 and MGMT demonstrated that HMGA2, not MGMT, protected GB cells from TMZ-induced apoptosis and this protective role of HMGA2 was independent of p53 activity status. We and others have previously demonstrated an antiapoptotic function of HMGA2 (Natarajan et al., 2013; Shi et al., 2016). Thus, the reduced HMGA2 protein levels contributed to increased apoptosis in GB cells exposed to dual Dov/TMZ treatment.

We devised a sequential treatment regimen starting with ‘Dov priming’ to attenuate DNA repair and...
Dovitinib increases TMZ efficacy in GB

T. Thanasupawat et al.

antiapoptotic capacities, followed by TMZ treatment to induce DNA base lesions in an attempt to improve the efficacy of both drugs in GB cells. Sequential Dov/TMZ treatment significantly reduced cell viability by 40% and 30% in patient GB cells and U251 cells, respectively, compared to TMZ or Dov single treatments. Importantly, just two cycles of sequential Dov/TMZ treatment followed by a final Dov treatment and subsequent 9 days of treatment-free recovery period significantly reduced or almost inhibited colony formation with U251 and patient GB cells, respectively. These results showed that the sequential dual-hit Dov/TMZ treatment can dramatically reduce or inhibit long-term survival of GB cells. This effect was independent of the MGMT status of the GB cells. The increased dsDNA damage and enhanced apoptotic cell death upon combined Dov/TMZ treatment were both linked to diminished cellular HMG2A levels. U251-HMGA2 transfectants with overexpression of exogenous HMGA2 were partially protected from this increased DNA damage and apoptosis upon dual Dov/TMZ treatment. Importantly, we observed a similar protective effect of HMGA2 on radiation-induced DNA damage in GB cells. Recently, Dov has been described as a radiosensitizer for hepatocellular carcinoma (Huang et al., 2016). Our discovery suggests that HMGA2 may facilitate this radiosensitizing function of Dov in GB.

5. Conclusion

Dov treatment attenuated the STAT3/LIN28/Let-7/HMGA2 axis and expression of specific BER factors and MGMT proteins. This resulted in increased TMZ sensitivity, reduced DNA repair capacity, increased dsDNA breaks and the induction of apoptosis in mouse and human GB cells. The combination of Dov and TMZ treatments reduced GB growth and self-renewal capacity and severely compromised the recovery of GB cells. When administered in an alternating sequence, a regimen of ‘Dov priming’ and subsequent TMZ-induced DNA alkylation may improve the therapeutic efficacy of current stand-alone TMZ treatments, particularly in patients with MGMT+ GB and functional p53 status who are expected to have higher TMZ resistance. The concept of ‘Dov priming’ is a promising novel therapeutic strategy to improve TMZ efficacy in patients with GB.

Acknowledgements

The authors are grateful to Farhana Begum and Aditya Kumar Kanojia for technical support. We thank Dr. Brian Hasinoff, College of Pharmacy, University of Manitoba, for generously providing dovitinib and Dr. E. Weber, Physiological Chemistry, Martin-Luther-University Halle-Wittenberg, Germany, for providing the antibody to cathepsin B. We thank Dr. Marc DelBigio, Department of Pathology, University of Manitoba, for providing human glioblastoma tissues. This work was supported by Research Manitoba (SHK), National Science and Engineering Research Council of Canada, NSERC (SHK, TK), Cancer Research Society, CRS (TK, SHK), and the Department of Surgery Research Fund (JK, JB, TK, and SHK). This work was supported in part by grants from the NIH (R01 CA195613-20, P30 CA014195-38 and T32 CA009370), Ipen, the H.N. and Frances C. Berger Foundation, the Glenn Center for Aging Research, and the Leona M. and Harry B. Helmsley Charitable Trust grant #2017-PG-MED001.

Author contributions

TK and SHK designed the project, interpreted the data, wrote the manuscript, and provided funding. TT, SN, AR, and AG acquired the data. SG performed and designed flow cytometry. HB critically read the manuscript. IMV provided the mouse model. JK, JB, and MP provided surgical GB tissues and patient information. SHK made the pathology assessment of tumors. SK made the pathology assessment of tumors.

References

Angevin E, Lopez-Martín JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M et al. (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. *Clin Cancer Res* 19, 1257–1268.

Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM and Fusco A (1999) The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. *Cancer Res* 59, 4793–4797.

Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S and Escudier B (2013) Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. *Clin Genitourin Cancer* 11, 128–133.

Bobola MS, Kolstoe DD, Blank A, Chamberlain MC and Silber JR (2012) Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide. *Front Oncol* 2, 176.
Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ and Cheng AL (2012) Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. *Biochem Pharmacol* **83**, 769–777.

Choi JY, Ghiendis E, Giraldo Hernandez CA, Shin M, Iacovelli L, Xiao X, Gopalakrishnan V, Dzik-Wasik M,anna G, Rapp U, Datta SR, Hothorn T, Glass DJ, Bassani SV and Ciliberto G (2014) Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. *Antimicrob Agents Chemother* **58**, 693–706.

Chon HJ, Lee Y, Bae KJ, Byun BJ, Kim SA and Kim J (2016) Traf2- and Nck-interacting kinase (TNK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. *Antimicrob Agents Chemother* **58**, 693–706.

Droge P and Davey CA (2008) Do cells let-7 determine stemness? *Cell Stem Cell* **2**, 8–9.

Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J, Llombart-Cussac A, Matias-Guiu X and Valls J (2016) Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. *Cancer Chemother Pharmacol* **78**, 653–663.

Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J, Llombart-Cussac A, Matias-Guiu X and Valls J (2014) Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells. *Mol Cancer Ther* **13**, 776–787.

Escudier B, Glisson B, Kollmannsberger P, Motzer RJ, Oudard S, pdb S, de Tribolet N, Juweid ME, Redman MJ, Schrump DS, Michaelson MD, Motzer RJ, Oudard S, umb S, de Tribolet N, Juweid ME, Redman MJ, Schrump DS and Maki RG (2013) Cetuximab plus chemotherapy as first-line treatment of metastatic colorectal cancer. *Neoplasia* **15**, 1233–1243.

Fan LC, Teng HW, Shiau CW, Tai WT, Hung MH, Yang SH, Jiang JK and Chen KF (2015) Pharmacological targeting SHP-1-STAT3 signaling is a promising therapeutic approach for the treatment of colorectal cancer. *Neoplasia* **17**, 687–696.

Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH and Verma IM (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science* **338**, 1080–1084.

Fukushima T, Takeshima H and Kataoka H (2009) Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. *Anticancer Res* **29**, 4845–4854.

Gavriel M, Shindo C, Tsuchiya A, Kojima H, Itoh M, Nakamura A, Nakanishi H and Miki T (2016) Phosphorylation of Smad2 by Src contributes to the growth of human cancer cells. *Neoplasia* **18**, 913–925.

Ghavami S, Eshraghi M, Kadkhoda K, Mutawe MM, Maddika S, Bay GH, Wesselborg S, Halayko AJ, Klonisch T and Los M (2009) Role of BNI3P in TNF-induced cell death–TNF upregulates BNI3P expression. *Biochim Biophys Acta* **1793**, 546–560.

Ghavami S, Mutawe MM, Hauff K, Stelmack GL, Schafsma D, Sharma P, McNeill KD, Hynes TS, Kung SK and Unruh H et al. (2010) Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. *Biochim Biophys Acta* **1803**, 452–467.

Glogowska A, Kunanuvat U, Stetefeld J, Patel TR, Thanasupawat T, Kreck J, Weber E, Wong GW, Del Bigio MR and Huang Y et al. (2013) Clq-tumour necrosis factor-related protein 8 (CTRF8) is a novel interaction partner of relaxin receptor RXFP1 in human brain cancer cells. *J Pathol* **231**, 466–479.

Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G and Huang S (2015) FoxM1 drives a feed-forward STAT3-activation signaling loop that promotes the self-renewal and tumorigenicity of glioblastoma stem-like cells. *Cancer Res* **75**, 2337–2348.

Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qiao L and Guo N (2013) Stat3-coordinated Lin-28-let-7-HMGAM and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. *Oncogene* **32**, 5272–5282.

Hammond SM and Sharpless NE (2008) HMGAM2, microRNAs, and stem cell aging. *Cell* **135**, 1013–1016.

Han TJ, Cho BJ, Choi EJ, Kim DH, Song SH, Paek SH and Kim IA (2016) Inhibition of STAT3 enhances the
Dovitinib increases TMZ efficacy in GB

Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S and Ma D et al. (2013) Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. *Biochem Biophys Res Commun* **435**, 188–194.

Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R and Yalowich JC (2012) The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. *Biochem Pharmacol* **84**, 1617–1626.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP and Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *J Clin Oncol* **26**, 4189–4199.

Hong X, Chedid K and Kalkanis SN (2012) Glioblastoma cell line-derived spheres in serum containing medium versus serum-free medium: a comparison of cancer stem cell properties. *Int J Oncol* **41**, 1693–1700.

Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH and Chen KF (2016) Dovitinib acts as a novel radiosensitizer in hepatocellular carcinoma by targeting SHP-1/STAT3 signaling. *Int J Radiat Oncol Biol Phys* **95**, 761–771.

Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH and Hynes NE (2013) Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. *Breast Cancer Res* **15**, R8.

Jiang W, Finniss S, Cazacu S, Xiang C, Brodie Z, Mikkelsen T, Poisson L, Shackelford DB and Brodie C (2016). Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. *Oncotarget* **7**, 56456–56470.

Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J and Ryu JS et al. (2013) Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. *Br J Cancer* **109**, 2309–2315.

Kaur H, Ali SZ, Huey L, Hutt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ and Eberhart CG et al. (2016) The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. *Cancer Lett* **377**, 55–64.

Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH and Bang YJ (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. *Cancer* **121**, 2612–2617.

Kim KB, Chesney J, Robinson D, Gardner H, Shi MM and Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. *Clin Cancer Res* **17**, 7451–7461.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD and Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. *Neuro Oncol* **11**, 281–291.

Konecny GE, Kolarova T, O’Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R and Luo T et al. (2013) Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. *Mol Cancer Ther* **12**, 632–642.

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O and Reifenberger G et al. (2007) Long-term survival with glioblastoma multiforme. *Brain* **130**, 2596–2606.

Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z and Rosenberg MW et al. (2015) The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. *Pigment Cell Melanoma Res* **28**, 417–430.

Lee CK, Lee ME, Lee WS, Kim JM, Park KH, Kim TS, Lee KY, Ahn JB, Chung HC and Rha SY (2015) Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. *Am J Cancer Res* **5**, 72–86.

Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL and Gelb AB et al. (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. *Clin Cancer Res* **11**, 3633–3641.

Li O, Li J and Droge P (2007) DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. *FEBS Lett* **581**, 3533–3537.

Lim SM, Chung WY, Nam KH, Kang SW, Lim JY, Kim HG, Shin SH, Sun JM, Kim SG and Kim JH et al. (2015) An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. *Eur J Cancer* **51**, 1588–1595.

Liu B, Pang B, Hou X, Fan H, Liang N, Zheng S, Feng B, Liu W, Guo H and Xu S et al. (2014) Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. *Hum Pathol* **45**, 1752–1758.

Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C...
and Oei Y et al. (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. *Clin Cancer Res* **11**, 5281–5291.

Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K and Tandle AT (2016) FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. *Oncotarget* **7**, 77365–77377.

Mao XG, Hutt-Cabezas M, Orr BA, Weingart M, Mayr C, Hemann MT and Bartel DP (2007) Disrupting the Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Nitiss JL (2009) Targeting DNA topoisomerase II in cancer

Natarajan S, Hombach-Klonisch S, Droge P and Klonisch T (2013) HMG2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. *Neoplasia* **15**, 263–280.

Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer* **9**, 338–350.

Peter S, Yu H, Ivanj-Nagy R and Droge P (2016) Cell-based high-throughput compound screening reveals functional interaction between oncopetal HMG2 and topoisomerase I. *Nucleic Acids Res* **44**, e162.

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacomuzzi S, Aprire G, Simionato F, Boschi F, Zanotto M, Mina MM et al. (2016) An FGFR3 autocrine loop sustains acquired resistance to Trastuzumab in gastric cancer patients. *Clin Cancer Res* **22**, 6164–6175.

Portnow J, Badie B, Chen M, Liu A, Blanchard S and Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. *Clin Cancer Res* **15**, 7092–7098.

Powles T, Foreshew SJ, Shamash J, Sarwar N, Crab S, Sahdev A, Nixon J, Lim L, Pungaliya A, Foreshaw A et al. (2014) A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. *Eur J Cancer* **50**, 2057–2064.

Qin R, Zhou J, Chen C, Xu T, Yan Y, Ma Y, Zheng Z, Shen Y, Lu Y, Fu D et al. (2014) LIN28 is involved in glioma carcinogenesis and predicts outcomes of glioblastoma multiforme patients. *PLoS ONE* **9**, e86446.

Quintel-Fando M, Bueno MJ, Lombardia L, Gil M, Gonzalez-Martín A, Marquez R, Bratos R, Guerra J, Tan E, Lopez A et al. (2014) Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial. *Mol Oncol* **8**, 1719–1728.

Quiros S, Roos WP and Kaina B (2010) Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. *Cell Cycle* **9**, 168–178.

Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U and Bullerdiek J (1997) Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. *Mol Carcinogen* **19**, 153–156.

Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multikinased receptor tyrosine kinase inhibitor in patients with advanced solid tumors. *Clin Cancer Res* **14**, 2075–2081.

Schafer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reintartz R, Niessen M et al. (2016). Phase I trial of dovitinib (TK1258) in recurrent glioblastoma. *J Cancer Res Clin Oncol* **142**, 1581–1589.

Scheid C, Reece D, Bekas M, Spencer A, Callander N, Sonneveld P, Kaligi M, Cai C, Shi M, Scott JW et al. (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. *Eur J Haematol* **95**, 316–324.

Sharma A, Singh K and Almasan A (2012) Histone H2AX phosphorylation: a marker for DNA damage. *Methods Mol Biol* **920**, 613–626.

Shi Z, Wu D, Tang R, Li X, Chen R, Xue S, Zhang C and Sun X (2016) Silencing of HMGA2 promotes apoptosis and inhibits migration and invasion of prostate cancer cells. *J Biol* **41**, 229–236.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10, 459–466.

Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, Henderson D, Klonisch T, Goodman SD and Droge P (2009) HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. *Nucleic Acids Res* 37, 4371–4384.

Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ and Chen KF (2012) Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. *Mol Cancer Ther* 11, 452–463.

Tang JB, Sivaldi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR and Sobol RW (2011) N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. *Neuro Oncol* 13, 471–486.

Thanasupawat T, Bergen H, Hombach-Klonisch S, Krcek J, Ghavami S, Del Bigio MR, Krawitz S, Stelmack G, Halayko A, McDougall M et al. (2015). Platinum (IV) coiled coil nanotubes selectively kill human glioblastoma cells. *Nanomedicine* 11, 913–925.

Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C and Stewart AK (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood* 105, 2941–2948.

Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. *Cell* 156, 1002–1016.

Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K et al. (2016) Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. *Cancer Lett* 380, 163–173.

Weingart MF, Roth JJ, Hutt-Cabezaz M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG et al. (2015) Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. *Oncotarget* 6, 3165–3177.

Woodhouse BC, Dianova II, Parsons JL and Dianov GL (2008) Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks. *DNA Repair (Amst)* 7, 932–940.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* 131, 1109–1123.

Zaidi MR, Okada Y and Chada KK (2006) Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. *Cancer Res* 66, 7453–7459.

Zang C, Eucker J, Habbel P, Neumann C, Schulz CO, Bangemann N, Kissner L, Riess H and Liu H (2015) Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer. *Cell Cycle* 14, 1291–1299.

Zhong X, Liu X, Li Y, Cheng M, Wang W, Tian K, Mu L, Zeng T, Liu Y, Jiang X et al. (2016). HMGA2 sustains self-renewal and invasiveness of glioma-initiating cells. *Oncotarget* 7, 44365–44380.

Zhong Z, Wen Z and Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. *Science* 264, 95–98.

**Supporting information**

Additional Supporting Information may be found online in the supporting information tab for this article:

- **Fig. S1.** HMGA2 silencing impairs sphere formation.
- **Fig. S2.** HMGA2 is expressed in human and mouse GB cells.
- **Fig. S3.** Dovitinib mediated specific down-regulation of endogenous HMGA2.
- **Fig. S4.** Temozolomide depletes MGMT but does not regulate BER factors in GB.
- **Fig. S5.** HMGA2 and MGMT knockdown by siRNA are not toxic to GB cells.
- **Fig. S6.** Dovitinib caused lasting MGMT protein reduction.
- **Fig. S7.** P53 expression and functionality.
- **Fig. S8.** HMGA2 protects against radiation-induced DNA damage in GB cells.